健康科学收购公司 2（纳斯达克股票代码：HSAQ）与 Delcath Systems（纳斯达克股票代码：DCTH）的财务对比

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ – Get Rating) and Delcath Systems (NASDAQ:DCTH – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Delcath Systems' net margins, return on equity and return on assets.

Get Health Sciences Acquisitions Co. 2 alerts:

Insider & Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 25.7% of Delcath Systems shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 16.8% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Health Sciences Acquisitions Co. 2 and Delcath Systems, as reported by MarketBeat.

Delcath Systems has a consensus target price of $17.33, suggesting a potential upside of 237.22%. Given Delcath Systems' higher probable upside, analysts plainly believe Delcath Systems is more favorable than Health Sciences Acquisitions Co. 2.

Earnings & Valuation

This table compares Health Sciences Acquisitions Co. 2 and Delcath Systems' gross revenue, earnings per share and valuation.

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Delcath Systems.

Summary

Health Sciences Acquisitions Co. 2 beats Delcath Systems on 6 of the 10 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

(Get Rating)

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Delcath Systems

(Get Rating)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Receive News & Ratings for Health Sciences Acquisitions Co. 2 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Sciences Acquisitions Co. 2 and related companies with MarketBeat.com's FREE daily email newsletter.